Orlistat for the treatment of obesity: Rapid review and cost-effectiveness model

Obesity Reviews

Volumn 1, Issue 2, 2000, Pages 121-126

  Foxcroft, D R ^a,c   Milne, R ^b  

^a OXFORD BROOKES UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^c Oxford Centre for Health R and D   (United Kingdom)

Author keywords

Cost effectiveness; Orlistat; Quality of life

Indexed keywords

ANTIOBESITY AGENT; LACTONE; TETRAHYDROLIPSTATIN;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COST BENEFIT ANALYSIS; ECONOMICS; HUMAN; MORTALITY; OBESITY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ANTI-OBESITY AGENTS; COST-BENEFIT ANALYSIS; HUMANS; LACTONES; OBESITY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS;

EID: 0034289840     PISSN: 14677881     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1467-789x.2000.00011.x     Document Type: Review

References (24)

1. European Agency for the Evaluation of Medicinal Products (EMEA). (1998). Committee for Proprietary Medicinal Products European Public Assessment Report (EPAR): Xenical. [WWW Document] URL http://www.eudra.org/humandocs/PDFs/EPAR/ 106698rn.pdf
2. National Institute of Clinical Excellence (NICE). (2000). Homepage. [WWW Document] URL http://www.nice.org.uk
3. Foxcroft D, Ludders J. (1999). Orlistat for the treatment of obesity. Southampton: Wessex Institute for Health Research and Development; 1999 September. Development and Evaluation Committee Report no. 101. [WWW document] URL http://www.hta.nhsweb.nhs.uk/rapidhta
4. Critical Appraisal Skills Progamme. (1999). Checklists. [WWW document] URL http://www.public-health.org.uk/casp
5. Rosser R, Allison R, Butler C, Cottee M, Rabin R, Selai C. The Index of Health-related Quality of Life (IHQL): a new tool for audit and cost-per-QALY analysis. In: Walker SR, Rosser RM (eds). Quality of Life assessment: Key issues in the 1990s. MTM Press: London, 1993, pp 157-196.
6. Sjöström L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HPF, Krempf M. Randomised placebo-controlled trial of Orlistat for weight loss and prevention of weight regain in obese patients. Lancet 1998; 352: 167-173.
7. Davidson MH, Hauptman J, DiGirolamo M, Foreyt JP, Halsted CH, Heber D, Heimburger DC, Lucas CP, Robbins DC, Chung J, Heymsfield SB. Weight control and risk factor reduction in obese subjects treated for 2 years with Orlistat. JAMA 1999; 281: 235-242.
8. Hollander PA, Elbein SC, Hirsch IB, Kelley D, McGill J, Taylor T, Weiss SR, Crockett SE, Kaplan RA, Comstock RA, Lucas CP, Lodewick PA, Canovatchell W, Chung J, Hauptman J. Role of Orlistat in the treatment of obese patients with type 2 diabetes. Diabetes Care 1998; 21: 1288-1294.
9. Royal College of Physicians. Clinical management of overweight and obese patients with particular reference to the use of drugs. RCP: London, 1998.
10. Jung RT. Obesity as a disease. Br Med Bull 1997; 53: 307-321.
11. Williamson DF, Pamuk E, Thun M, Flanders D, Byers T, Heath C. Prospective study of intentional weight loss and mortality in overweight white men aged 40-64 years. Am J Epidemiol 1999; 149: 491-503.
12. Allison DB, Zannolli R, Faith MS, Heo M, Pietrobelli A, Van-Itallie TB, Pi-Sunyer FX, Heymsfield SB. Weight loss increases and fat loss decreases all-cause mortality rate: results from two independent cohort studies. Int J Obes Relat Metab Disord 1999; 23: 603-611.
13. Cerulli J, Malone M. Outcomes of pharmacological and surgical treatment for obesity. Pharmacoeconomics 1998; 14: 269-283.
14. Fontaine KR, Cheskin LJ, Barofsky I. Health-related quality of life in obese persons seeking treatment. J Fam Pract 1996; 43: 265-270.
15. Barofsky I, Fontaine KR, Cheskin LJ. Pain in the obese: impact on health related quality of life. Ann Behav Med 1997; 19: 408-410.
16. Lean MEJ, Han TS, Seidell JC. Impairment of health and quality of life in people with large waist circumference. Lancet 1998; 351: 853-856.
17. Lean MEJ, Han TS, Seidell JC. Impairment of health and quality of life using new US federal guidelines for the identification of obesity. Arch Intern Med 1999; 159: 837-843.
18. Van Gemert WG, Adang EM, Greve JWM, Soeters PB. Quality of life assessment of morbidly obese patients: effect of weight reducing surgery. Am J Clin Nutr 1998; 67: 197-201.
19. Karlsson J, Sjöström L, Sullivan M. Swedish obese subjects (SOS) - an intervention study of obesity. Two year follow-up of health related quality of life (HRQL) and eating behavior after gastric surgery for severe obesity. Int J Obesity 1998; 22: 113-126.
20. Shah M, McGovern P, French S, Baxter J. Comparison of a low-fat, ad libitum complex-carbohydrate diet with a low-energy diet in moderately obese women. Am J Clin Nutr 1994; 59: 980-984.
21. James W, Avenel A, Broom J, Whitehead J. A one year trial to assess the value of Orlistat in the management of obesity. Int J Obes Relat Metab Disord 1997; 21: S24-S30.
22. Bryant J, Best L, Milne R. (1997). Gastroplasty for severe obesity. Southampton: Wessex Institute for Health Research and Development; 1997 March. Development and Evaluation Committee Report no. 68 [WWW document] URL http://www.hta. nhsweb.nhs.uk/rapidhta
23. Pickin MD, Payne JN, Haq IU, McCabe CJ, Ward SE, Jackson PR, Yeo WW. (1996).Statin Therapy / HMG Co-A Reductase Inhibitor Treatment in the Prevention of Coronary Heart Disease 1996 Sheffield: Trent Institute for Health Services Research; 1996 Working Group on Acute Purchasing Report no. 96/04 [WWW document] URL http://www.shef.ac.uk/uni/academic/R-Z/tiwgap/ report.htm
24. Drummond M, Torrance G, Mason J. Cost-effectiveness league tables: more harm than good? Soc Sci Med 1993; 37: 33-40.